Controlled multinational research presented at EADV 2026 shows GLP-1 drug users face significantly higher rates of nail detachment (39% vs 9%) and hair loss (50% vs 34%) than non-users, with scalp inflammation suggesting mechanisms beyond weight loss. Concurrently, pharmaceutical companies Eli Lilly and Novo Nordisk face at least 90 US lawsuits alleging vision loss from NAION, while emerging research explores potential anti-aging effects on biological clock markers.
Nail disorders linked to GLP-1 use
- ▪A study presented at the European Academy of Dermatology and Venereology Congress 2026 revealed that 66% of GLP-1 users experienced at least one nail disorder, compared to 53% of non-users.
- ▪In a controlled study presented at the European Academy of Dermatology and Venereology Congress 2026, 39% of GLP-1 medication users reported nail detachment compared with 9% of non-users.
- ▪Researchers presenting at the European Academy of Dermatology and Venereology Congress 2026 found that nail detachment remained two to three times more common among GLP-1 users after adjusting for weight loss, existing skin conditions, and nutritional deficiencies.
Hair loss associated with GLP-1 drugs
- ▪A companion study presented at the European Academy of Dermatology and Venereology Congress 2026 reported that hair loss beginning after treatment started occurred in 26% of GLP-1 users versus 12% of non-users.
- ▪Researchers presenting at the European Academy of Dermatology and Venereology Congress 2026 noted that hair loss in GLP-1 users was typically accompanied by scalp redness, itching, or scaling, suggesting an inflammatory mechanism.
- ▪In a companion study evaluating hair health among 575 GLP-1 users and 1,329 controls, 50% of GLP-1 users reported unusual hair shedding compared to 34% of non-users.
- ▪A study presented at the European Academy of Dermatology and Venereology Congress 2026 showed that 42% of GLP-1 users experienced reduced hair volume or density compared with 19% of non-users.
Vision loss risks and regulatory warnings
- ▪The UK Medicines and Healthcare products Regulatory Agency issued a warning acknowledging a link between GLP-1 injections and non-arteritic anterior ischaemic optic neuropathy.
- ▪A 2025 study published in JAMA Network Open found that semaglutide and tirzepatide users were 76% more likely to develop non-arteritic anterior ischaemic optic neuropathy compared to users of other diabetes medications.
- ▪Non-arteritic anterior ischaemic optic neuropathy develops when blood flow to the optic nerve is blocked or reduced, causing sudden and often permanent vision loss.
Lawsuits Over vision loss claims
- ▪Drugmakers Novo Nordisk and Eli Lilly face at least 90 personal-injury lawsuits in the United States from GLP-1 users claiming the medications caused permanent vision loss.
- ▪Lawsuits filed against Novo Nordisk by personal-injury firm Weitz and Luxenberg allege that patients developed non-arteritic anterior ischaemic optic neuropathy while using Ozempic or Wegovy.
- ▪Novo Nordisk stated that the United States personal injury lawsuits regarding non-arteritic anterior ischaemic optic neuropathy lack merit and that no causal relationship has been established.
Gastrointestinal and pancreatic side effects
- ▪Gastrointestinal issues including nausea, vomiting, diarrhea, and constipation represent the most common side effects associated with GLP-1 receptor agonist medications.
- ▪GLP-1 receptor agonist medications have been clinically linked to an increased risk of pancreatitis and gallstone disease.
GLP-1 drugs and biological aging
- ▪Data presented by Eli Lilly from the Surmount V trial showed that 71 participants over age 50 using tirzepatide experienced a slowing of biological aging across epigenetic clocks relative to elapsed time.
- ▪A University of California, Berkeley study published in Nature found that 20-month-old mice treated with semaglutide lived an average of 834 days compared to 742 days for placebo-treated mice.
- ▪A Novo Nordisk preprint study reported that semaglutide reduced the heart's biological age by two to four years and reduced organ biological age by one to four years compared to placebo.
Debatable claims
- ▪Rapid weight loss is the primary cause of hair and nail damage in GLP-1 users
- ▪The metabolic health benefits of GLP-1 drugs outweigh their dermatological side effects
- ▪GLP-1 medications directly cause non-arteritic anterior ischaemic optic neuropathy
Story comments
Loading comments…